mortality are high as are relapse rates. [1] [2] [3] While some groups have reported reasonable results with second transplants in patients with relapsed acute leukemia, 4-14 these We studied 231 acute leukemia patients relapsing after allogeneic (n = 114) or autologous (n = 117) BMT to results may reflect the outcome of a highly selected group of patients because only a small proportion of relapsed assess the outcome of further therapy. In general, all patients in good condition were eligible for second patients is actually suitable for second grafts.
Summary:
mortality are high as are relapse rates. [1] [2] [3] While some groups have reported reasonable results with second transplants in patients with relapsed acute leukemia, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] these We studied 231 acute leukemia patients relapsing after allogeneic (n = 114) or autologous (n = 117) BMT to results may reflect the outcome of a highly selected group of patients because only a small proportion of relapsed assess the outcome of further therapy. In general, all patients in good condition were eligible for second patients is actually suitable for second grafts. 1, 2 Alternative approaches which have been used to treat transplants except for post-allograft relapses from 1993-1994 onwards who received cytokine-or cellrelapse after allogeneic BMT have included stimulation of donor-type hematopoiesis with filgrastim 15 and immunomediated immunotherapy. The major reason for patients not progressing to second graft was death from therapy. [16] [17] [18] [19] [20] [21] Cell-or cytokine-mediated adoptive immunotherapy is increasingly being utilized to treat acute leukeprogressive disease or toxicity of salvage chemotherapy. Seventeen of 231 patients (7%) were alive at the last mia relapsing after allogeneic BMT, and is a potentially useful and less toxic alternative to second allografts. [16] [17] [18] [19] [20] [21] follow-up. Six of 14 post-autograft relapses treated with second transplants were alive and well, compared with For patients relapsing after autografts, repeat autografting in a subsequent remission 22, 23 or allogeneic transplanfive of 103 not undergoing second grafts (P Ͻ 0.0001). One of 23 post-allograft recipients treated with second tation 14, 24 have been utilized as salvage therapy. The overall denominator of relapsing patients needs to be taken into allografts was alive with an extramedullary relapse, compared with five of 13 receiving immunotherapy and account to determine the exact place of second transplants in the management of relapsed acute leukemia; something none of 78 receiving standard-dose or palliative therapy (P Ͻ 0.0001). We conclude that only a small proportion which has usually not been done in previous retrospective analyses. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [22] [23] [24] of highly selected acute leukemia patients relapsing after a transplant reach the stage of a conventional This analysis was undertaken to assess the outcome of all acute leukemia patients relapsing after allogeneic or second transplant. In our experience, second allografts after myeloablative therapy in patients relapsing after autologous BMT between 1980 and August 1995 at our center to study the utility of second transplants and alternaone allograft are associated with very poor results, and immunotherapy may be a better approach in such cases.
tive therapy including immunotherapy. Selected patients relapsing after an autograft may become long-term survivors following a second autograft or an allograft. Keywords: acute leukemia; allogeneic bone marrow Patients and methods transplantation; autologous bone marrow transplantation; immunotherapy; relapse; repeat transplantation; salvage
The database of the Leukaemia Unit of the Royal Marsden Hospital contains prospectively collected comprehensive therapy data on over 1600 patients with hematologic malignancies treated in the unit since 1978. 25, 26 This was searched to identify 231 patients (147 male, 84 female) who had underThe prognosis of patients with acute leukemia who relapse gone autologous (including syngeneic) or allogeneic blood after allogeneic bone marrow transplantation (BMT) is very or marrow transplantation for acute leukemia between 1980 poor. 1, 2 Intensive chemotherapy results in remission in a and 1995, and who had relapsed following the procedure proportion of patients, but treatment-related morbidity and up to November 1995. Characteristics of these patients are shown in Table 1 . Patients who had received hematopoietic rescue with autologous material for primary failure of allo-710 The autograft group includes three syngeneic transplants. The P values represent the comparison of the autograft and allograft groups.
Treatment after relapse in the immunotherapy group. 18 Only patients conditioned with myeloablative doses of chemotherapy or chemoradioTreatment after relapse was heterogeneous, and varied therapy for the second allogeneic transplant procedure according to the diagnosis, disease stage at transplant, ('conventional allograft') were included in the second transpatient age, and most importantly, the general clinical conplant group. This distinction, in our opinion, is important dition. In general, patients in good clinical condition tended because while standard-dose chemotherapy is tolerated to receive combination induction chemotherapy. Acute reasonably well by patients relapsing after a transplant, myeloid leukemia (AML) patients received 3 + 7 type of high-dose therapy (in doses conventionally used for a standard therapy or high-dose cytarabine-based salvage transplant) is tolerated quite poorly. therapy. 28, 29 Acute lymphoblastic leukemia (ALL) patients received a vinca alkaloid with prednisolone and l-asparaginase with or without an anthracycline. Patients with poor performance status often received only supportive therapy Eligibility for second transplants or palliative chemotherapy. Sites of extramedullary disease were irradiated unless these sites (usually brain and spine)
All relapsing patients were considered eligible for second transplants if their clinical condition was good enough. had been irradiated before.
Patients receiving standard-dose induction chemotherapy However, in practice, barring some patients who underwent second transplants as primary salvage therapy, only patients which is non-myeloablative with infusion of donor blood cells (G-CSF-mobilized or non-mobilized) were included achieving a reasonable response (partial or complete) to sal-vage chemotherapy who were in good clinical condition, was plotted as an event. Among patients undergoing second transplants, survival was measured from the point of the or patients in excellent clinical condition irrespective of response to salvage chemotherapy reached the stage of a second transplant. Actuarial probabilities were compared using the log-rank test, and all other comparisons were second transplant. However, except for adult patients with ALL on the sequential high-dose therapy program (see made using the 2 test unless otherwise specified. below), no specific eligibility criteria existed for second transplants, and the final decision about a second transplant was most often made at the discretion of a senior attending physician.
Results Adult patients with ALL treated on the sequential highdose therapy program 30 underwent autologous peripheral Details of post-relapse management were not available for 36 patients because relapse was diagnosed elsewhere blood stem cell transplantation after 200 mg/m 2 melphalan in first remission, and received maintenance chemotherapy (usually in the patient's home country) or the patient was discharged to the care of the referring physician upon with 6-mercaptopurine and methotrexate for 2 years. Those who relapsed after the autograft received a single 4-week relapse and detailed information was not available. Twentynine of these were definitely reported to have died. The cycle of standard combination chemotherapy (vincristine, prednisolone, daunorubicin, and l-asparaginase) for reinremaining seven (four allografts, three autografts) were assumed to have died because of the clinical circumstances, duction of remission, and underwent an allograft from an HLA-identical sibling donor in second remission after conbut were excluded from statistical analysis. ditioning with 60 mg/kg etoposide and 1050 cGy singlefraction TBI.
30,31
The various conditioning regimens used (mentioned in Reinduction therapy the Tables) and standard supportive therapy have been described earlier.
18,30-36 Table 3 shows the treatment given after relapse and outcome. Of patients on whom information was available 65% (127 of 195) received reinduction therapy, and 45% of these (57 of 127) attained remission. All patients showing Immunotherapy partial or no response died of the disease or complications of therapy, as did most patients attaining remission (Table  This was used sporadically from late 1992 and 1993, but was offered to the majority of patients relapsing after an 3). There was no significant difference in remission rates between AML, ALL, and other acute leukemia patients (41 allograft from 1994 onwards. 18 The plan of immunotherapy consisted of cessation of immunosuppression with or withvs 48 vs 50%, P = 0.7), autograft and allograft recipients (52 vs 38%, P = 0.13), and those relapsing р1 or Ͼ1 year out donor cells and immunomodulating cytokines, with or without preceding standard-dose induction chemotherapy, after transplantation (40 vs 52%, P = 0.19). However, a significantly (P Ͻ 0.0001) higher proportion of patients and is outlined in Table 2 .
relapsing beyond 1 year (76%) actually received induction chemotherapy compared with patients relapsing within a year (44%). Stage of the disease at the time of transplant Statistical analysis did influence remission rates significantly: 55% for first remission, 35% for second remission, and 29% for other Data were analyzed as of 1 March 1996. For life-table analysis of the whole group, survival was measured from stages (P = 0.039). The outcome of patients experiencing marrow relapse was no different from those experiencing the point of relapse. Survivors were censored at the last follow-up and death due to any cause (treatment or toxicity) extramedullary relapse with or without marrow involvement. 23 of 114 patients relapsing after an allograft (P = 0.09). subcutaneously three times a week) if persistent disease or relapse after response to previous immunotherapy.
While recipients of second grafts and those not receiving second grafts tended to be of a comparable age (22 vs 26.5 712 GVHD (actuarial probability 44%). The 2-year probability of relapse in patients developing acute and/or chronic GVHD was 46% compared with 100% in patients developing neither (P= 0.005). years, P = NS), the median transplant-relapse interval for patients receiving second grafts was significantly longer (13 months, range 3-48) than for those not undergoing second grafts (6 months, range 1-46; P Ͻ 0.0001). Table 4 shows
Relapse after allografting the nature of the first and second transplants.
Of the 23 family allograft recipients undergoing second Seventeen patients relapsed following second transplants.
transplants, 22 were transplanted from the same donor. No The actuarial probability of relapse at 2 years following a patient received a T cell depleted graft, and GVHD prophysecond transplant was 74.9% ( Figure 1 ). Fourteen patients laxis consisted of cyclosporine as a single agent for all Karnofsky score 100%) chronic GVHD, or limited chronic GVHD with interstitial pneumonitis (n = 1, Karnofsky except the patient allografted from a different donor, who received cyclosporine and methotrexate. Table 5 shows score 80%), and one is alive with relapsed disease (Karnofsky score 80%) but no GVHD. The four in characteristics of these 23 patients by final outcome. The outcome was uniformly poor with no factor such as diagremission have complete donor-type chimerism, and the fifth has mixed myeloid chimerism (unstimulated nosis, stage, age or transplant-relapse interval predicting for toxic death or relapse.
karyotyping) and full donor-type lymphoid chimerism (PHA-stimulated karyotyping). As Figure 3 shows, patients receiving immunotherapy or second allografts have a significantly longer median survival than those who do not receive either of these. The interesting observation is that the only survivor on the second transplant curve has extensive chronic GVHD, Discussion interstitial pneumonitis, and an extramedullary relapse (bony deposit in the elbow).
Our experience suggests that a proportion of patients with acute leukemia can become long-term survivors despite relapse following a transplant procedure. While around half of the relapsing patients are actually well enough to receive Relapse after autografting reinduction chemotherapy (patients relapsing beyond 1 year are much more likely to be well enough) and half of these Of the 14 autograft recipients undergoing second transplants, seven received second autografts using marrow harattain remission (much more likely for patients relapsing after first remission transplants), only a small proportion of vested in a subsequent remission, three received repeat syngeneic grafts, and four received allografts (three from HLAall relapsing patients actually receive a second graft. The overall applicability of second transplant procedures in the identical siblings and one from a phenotypically matched unrelated donor). Characteristics of these 14 patients, six setting of acute leukemia relapsing after transplantation is therefore limited. of whom are alive and well with Karnofsky scores of 100%, are shown in Table 6 . No specific characteristic was predicIt is noteworthy that only patients in complete remission at the time of the second transplant became long-term surtive of long-term survival following a second transplant.
In the non-transplant group, five patients are currently vivors in our population. In a study from the IBMTR, 10 the 2-year leukemia-free survival was 34% for 26 acute leukealive. Two children with ALL (aged 5 and 14 at the time of autografting in second and third remission, respectively) mia patients receiving a second allograft in remission, and 2% for the 49 patients not in remission at the time of the attained remission with conventional chemotherapy following relapse, and are in continuous remission at 9.5 and 3.5 second allograft. Therefore, reinduction chemotherapy should be administered to all patients considered candidates years, respectively, with Karnofsky scores of 100%. Two adults, who are in second remission with Karnofsky scores for second grafts. Second transplants should probably not be performed in patients not attaining remission or as of 90%, are awaiting allografts from an HLA-identical sibling (ALL) or an unrelated donor (AML). One adult with primary salvage therapy. Although toxicity was considerable following second AML has refractory, slowly progressive disease and is on palliative therapy (Karnofsky score 80%). grafts, the major problem was relapse. Because the number of patients receiving second grafts within a year of the first As Figure 4 shows, patients undergoing second transplants for relapse after a prior autograft have a significantly was small, we were unable to confirm Sanders et al's observation 7 that patients receiving second marrow transplants better chance of survival than those who do not.
at least 1 year after the initial transplant were more likely to survive long-term compared with those regrafted within 1 year.
Immunotherapy
All the double allografts were performed prior to 1992, and most before 1990. It is possible that relatively limited Thirteen patients received cytokine-and/or cell-mediated immunotherapy between December 1992 and 1995, some supportive care available then compared with recent, improved supportive care that the immunotherapy patients of whom have been described in detail elsewhere. 18, 37, 38 Two patients who received immunotherapy following received may have contributed to a better outcome in the latter group. Also, the relatively advanced disease at first relapse after second transplants have not been considered with this group of patients. The actual treatment received (13 first remission, 10 beyond) and at second allograft (13 first relapse or second remission, 10 beyond) may have conby individual patients was variable and has been shown in Table 7 . Response was not evaluable in five patients due tributed to the poor outcome of this group. The poor results we have obtained with double allografts do not necessarily to toxic death, one died of GVHD after attaining remission, three responded and relapsed (one still alive), and four are detract from better results obtained by other groups because careful selection of only a small fraction of relapsing alive and well at 10, 20, 20 and 30 months (Table 7 ). It is difficult to assess if G-CSF-mobilized cells (only from patients is likely to be vital for success of second allografts. Barrett et al 8 and Radich et al 12 showed the favorable related donors) were any different from non-mobilized cells (only from unrelated donors).
effect of GVHD on maintaining remission following the second transplant. Our observation confirms this; not only Four of the five survivors are in remission with extensive (n = 2, Karnofsky scores 80 and 90%) or limited (n = 1, for second transplants but also for immunotherapy. 18 The 714 problem, as expected, is the mortality associated with GVHD in extensively pretreated patients.
Second autografts may be useful in selected cases. This may be especially so for patients who have received relatively suboptimal therapy prior to the first transplant. This may have been the case for two of our surviving patients (Table 6 ) who received induction and consolidation chemotherapy without an anthracycline agent. However, both received anthracycline-containing induction and consolidation therapy after relapse before the second autograft. A third survivor with acute promyelocytic leukemia did not receive tretinoin prior to the first graft, but received it prior to the second. In patients treated optimally initially, allogeneic transplantation may be useful due to associated graft-versus-leukemia effects. 39 However, it should be noted that three of four patients undergoing second allo- fourth patient, who had received TBI earlier, died of toxicity during the allograft. The current study is the only analysis of second transplants which takes the entire denominator of relapsing patients into account, and therefore accurately highlights the limited applicability of second transplants. In the only other study which considered the patient denominator, Frassoni et al 1 on the behalf of the EBMT reported that only nine of 117 acute leukemia patients relapsing after allogeneic BMT received second transplants.
Although results of second allografts are disappointing, those of immunotherapy are encouraging with four potential long-term survivors (excluding one patient who is alive with disease) out of 13 patients. Other groups have also shown that adoptive immunotherapy is successful in inducing and maintaining remission of acute leukemia in patients with post-allograft relapse. 17, 20 Although its morbidity and mortality are considerable, it is better tolerated than conventional second allografts and may be applicable grafts should therefore probably be abandoned in favor of 716 Table 6 Characteristics of 14 patients undergoing a second transplant after a first autograft (n = 11; seven undergoing second autografts and four allografts) or a syngeneic transplant (n = 3; all three undergoing repeat syngeneic transplants) 6-MP = 6-mercaptopurine; 6-TG = 6-thioguanine; BuCy2/4 = 16 mg/kg busulfan + 120/200 mg/kg cyclophosphamide; Cy-TBI = 120 mg/kg cyclophosphamide + 950-1150 cGy single-fraction TBI; DNR = daunorubicin; DOX = doxorubicin; Melphalan-TBI = 110 mg/m 2 (*140 mg/m 2 ) melphalan + 1050 cGy single-fraction total-body irradiation; VCR = vincristine; VDAP = vincristine, daunorubicin, l-asparaginase, prednisolone. a Did not receive any anthracycline agents during initial therapy (prior to the first transplant). b Cyclosporine after autografting to induce graft-versus-host disease. c Did not receive tretinoin during initial therapy (prior to the first transplant). d Unrelated donor transplant e Marrow as well as central nervous system relapse. f Breast as well as central nervous system relapse, but marrow in remission. No systemic chemotherapy prior to allograft; treated with local radiation and intrathecal chemotherapy. BuCy2 = 16 mg/kg busulfan + 120 mg/kg cyclophosphamide; CsA = cyclosporine; Cy-FTBI = 120 mg/kg cyclophosphamide + 1200 cGy fractionated total body irradiation; Cy-Mel-FTBI = Cy-FTBI + 50 mg/m 2 melphalan; Cy-Mel-TLI-TBI = 50 mg/kg cyclophosphamide + 110 mg/m 2 melphalan + 900 cGy fractionated total lymphoid irradiation + 1200 cGy fractionated total body irradiation; IFN = interferon-␣2b; IL-2 = interleukin-2; Refr = primary refractory (induction failure); Melphalan-TBI = 110 mg/m 2 melphalan + 1050 cGy single-fraction total-body irradiation; sAML = secondary (treatmentrelated) acute myeloid leukemia. a Ex vivo T cell depletion with Campath-1G. All donor cells except those from unrelated donors were mobilized using G-CSF.
immunotherapy in the majority of patients. Currently availpatients can become long-term survivors even after a able data, including ours, are not sufficient to evaluate the relapse following marrow transplantation. The applicability merits of various approaches of immunotherapy. Treatment of second transplants in patients with acute leukemia may be best individualized depending upon the clinical relapsing after one procedure is limited because only a situation because, as Table 7 shows, the actual immunosmall proportion of highly selected patients reach the stage therapy received by survivors was variable.
of a second graft. Some patients relapsing after an autograft An important issue we have not addressed is that of qualmay become long-term survivors following a second autoity of life and palliation of symptoms. A large number of graft or an allograft; especially patients electively autopatients with acute leukemia relapsing after one transplant grafted with a view to allografting in second remission, or are unfortunately terminally ill. The most appropriate patients whose therapy prior to the first transplant may be course of action in patients who are unwell is judicious use considered suboptimal. A proportion of patients receiving of supportive/palliative therapy to improve quality of life immunotherapy may become long-term survivors with less and alleviate symptoms. Whether active intervention or morbidity than conventional second allograft procedures. supportive therapy is chosen for an individual patient Second allografts in patients relapsing after one allograft depends upon the performance status, extent and type of are associated with poor results, and should probably be previous therapy, stage of the disease, availability of abandoned in favor of immunotherapy in the majority of realistic treatment options beyond induction chemotherapy patients. (eg allogeneic donor), and patient preference.
We conclude that a small proportion of acute leukemia
